Literature DB >> 7599630

Transthyretin mutations in health and disease.

M J Saraiva1.   

Abstract

To date, over 40 different mutations in transthyretin (TTR) have been associated with amyloid deposition. The major unresolved problem is the correlation between the clinical heterogeneity and the genetic heterogeneity. For instance, whereas some mutations produce neuropathy and some give rise to cardiomyopathy, others produce vitreous opacities, the vast majority being neuropathic. Moreover, some mutations are not amyloidogenic but are responsible to hyperthyroxinemias (by virtue of the protein function in thyroid transport), whereas others are apparently nonpathogenic. The study of TTR variants is very important to the understanding of the amyloid formation process and to establish a relationship between the structure and function of the molecule. The results of current TTR mutation screening programs and their characterization are summarized.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7599630     DOI: 10.1002/humu.1380050302

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  51 in total

1.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Authors:  Christine E Bulawa; Stephen Connelly; Michael Devit; Lan Wang; Charlotte Weigel; James A Fleming; Jeff Packman; Evan T Powers; R Luke Wiseman; Theodore R Foss; Ian A Wilson; Jeffery W Kelly; Richard Labaudinière
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

2.  A new isoleucine substitution of Val-20 in transthyretin tetramers selectively impairs dimer-dimer contacts and causes systemic amyloidosis.

Authors:  D E Jenne; K Denzel; P Blätzinger; P Winter; B Obermaier; R P Linke; K Altland
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 3.  Beta arcades: recurring motifs in naturally occurring and disease-related amyloid fibrils.

Authors:  Andrey V Kajava; Ulrich Baxa; Alasdair C Steven
Journal:  FASEB J       Date:  2009-12-23       Impact factor: 5.191

4.  The molecular interaction of 4'-iodo-4'-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation.

Authors:  M P Sebastião; G Merlini; M J Saraiva; A M Damas
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

5.  A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.

Authors:  Sungwook Choi; Jeffery W Kelly
Journal:  Bioorg Med Chem       Date:  2010-12-30       Impact factor: 3.641

6.  Detection of metals and metalloproteins in the plasma of stroke patients by mass spectrometry methods.

Authors:  Phanichand Kodali; Karnakar R Chitta; Julio A Landero Figueroa; Joseph A Caruso; Opeolu Adeoye
Journal:  Metallomics       Date:  2012-09-14       Impact factor: 4.526

Review 7.  Pathophysiology and treatment of cardiac amyloidosis.

Authors:  Morie A Gertz; Angela Dispenzieri; Taimur Sher
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

8.  Rare Genetic Variants of the Transthyretin Gene Are Associated with Alzheimer's Disease in Han Chinese.

Authors:  Qun Xiang; Rui Bi; Min Xu; Deng-Feng Zhang; Liwen Tan; Chen Zhang; Yiru Fang; Yong-Gang Yao
Journal:  Mol Neurobiol       Date:  2016-08-25       Impact factor: 5.590

9.  Autoimmune response to transthyretin in juvenile idiopathic arthritis.

Authors:  Cristina C Clement; Halima Moncrieffe; Aditi Lele; Ginger Janow; Aniuska Becerra; Francesco Bauli; Fawzy A Saad; Giorgio Perino; Cristina Montagna; Neil Cobelli; John Hardin; Lawrence J Stern; Norman Ilowite; Steven A Porcelli; Laura Santambrogio
Journal:  JCI Insight       Date:  2016-02-25

10.  Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis.

Authors:  Satheesh K Palaninathan; Nilofar N Mohamedmohaideen; Elisabetta Orlandini; Gabriella Ortore; Susanna Nencetti; Annalina Lapucci; Armando Rossello; Joel S Freundlich; James C Sacchettini
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.